.Attributes Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of patients with HER2+ sophisticated breast cancer cells and also active or dependable brain metastases showed steady intracranial task as well as systemic efficiency of T-DXd.